What is LOPJLB’s current signal on EPIX?

LOPJLB’s latest quantitative signal on ESSA Pharma Inc. (EPIX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is EPIX in?

ESSA Pharma Inc. (EPIX) is currently classified in the CRISIS HMM market regime on LOPJLB.

ESSA Pharma Inc. (EPIX)

COMPARE

Healthcare · Biotechnology · NASDAQ · CA

$0.20+0.00%Close

SELLCRISIS · day 1

RANGE

DATA 2025-10-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $9M
Beta: 1.53

P/E (TTM): -0.31

1W: -9.09%
1M: +0.00%

vs SPY 1W: -10.25%
vs SPY 1M: -2.99%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing…

Employees: 35
Headquarters: CA
Founded: 2015
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 47.3M
Float: 94.0%

essapharma.com ↗

Key executives

David Ross Parkinson — President, Chief Executive Officer & Director

Peter A. Virsik — Executive Vice President & Chief Operating Officer

Alessandra Cesano — Chief Medical Officer & Executive Vice President

SEC filings

EDGAR · CIK 16339320 · EPIX

Analyst consensus

Hold

Bullish240.0%

Neutral360.0%

Bearish00.0%

L $2.00Avg $9.50H $17.00

Target$9.50+4650.00%

Last$0.20

FAQ

What is LOPJLB’s current signal on EPIX?: LOPJLB’s latest quantitative signal on ESSA Pharma Inc. (EPIX) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is EPIX in?: ESSA Pharma Inc. (EPIX) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does ESSA Pharma Inc. (EPIX) do?: ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-re…

Key stats

Prediction markets

Company news

FAQ